PhiC31 integrase brings the attB and attP DNA sites together and catalyzes their exchange. The reaction produces two new junctions, attL and attR, rather than preserving the original site pair. This change in site identity helps make the integration stable and generally unidirectional, supporting long-term maintenance of an inserted genetic sequence.
A generally unidirectional reaction favors movement from the attB and attP arrangement toward the attL and attR products. In bioengineering, that behavior helps an integrated transgene remain in place instead of readily returning to its starting configuration. The resulting stability is particularly useful for gene-expression studies and for engineering mammalian cell lines.
PhiC31 integrase does not require extensive stretches of matching DNA between an inserted construct and its chromosomal target. Instead, it relies on the defined attB and attP recognition sequences. This distinction can simplify the sequence requirements for stable insertion and provides an alternative to approaches that depend on long regions of homology.
The attB and attP sequences serve as the recognition points that specify where the recombination reaction can occur. Their presence gives the integrase a relatively simple molecular address for joining an engineered construct with a DNA target. After recombination, their conversion into attL and attR records that the integration event has taken place.
A construct is designed with an attB sequence, while the intended DNA target contains an attP sequence or is engineered to provide one. PhiC31 integrase is then supplied in the biological system so it can catalyze recombination between the sites. The expected outcome is formation of attL and attR together with stable insertion of the transgene.
PhiC31 integrase supports several applications that require genetic material to persist in cells. In mammalian systems, these include stable transgene integration, controlled gene-expression studies, and cell-line engineering. It is also relevant to experimental gene-therapy development, where a site-specific integration mechanism and limited homology requirements can be advantageous.